why choose us

First received: June 01, 2023

Clinical Trial: Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Anatomic Stage I Breast Cancer AJCC v8

Study Type: INTERVENTIONAL


Official Title: Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study

Brief Summary: This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer.Paclitaxel is in a class of medications called anti-microtubule agents.It stops cancer cells from growing and dividing and may kill them.Carboplatin is in a class of medications known as platinum-containing compounds.It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than…

Read more